Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVP-106
- Development stage
- Preclinical
- Lead developer
- Multiverse Pharma
- Administration
- Intravenous
01
Overview
MVP-106 is a preclinical-stage blood-brain barrier (BBB) shuttle developed by Multiverse Pharma. It is engineered to target the insulin-like growth factor 1 receptor (IGF-1R) to facilitate the transport of therapeutic payloads across the BBB via receptor-mediated transcytosis. This technology is intended to enable the delivery of drugs that are otherwise unable to penetrate the central nervous system, potentially addressing a wide range of neurological and neurodegenerative conditions.
Beyond the preview
Go deeper on MVP-106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVP-106.